 |
Quick Links |
| Information by Disease |
|
|
 |
| Cancer News |
|
|
 |
| Conference Coverage |
|
|
 |
| AZN | $44.82 | -0.37 (-0.82%)
| | NVS | $53.13 | -0.16 (-0.3%)
| | SNY | $37.67 | -0.01 (-0.03%)
| | GSK | $41.53 | 0.06 (0.14%)
|
|
 |
Graft-Versus-Host Disease
| Nipent (pentostatin) |
Antimetabolite |
SuperGen |
II |
| Nuvion (visilizumab) |
IgG2 antibody |
Protein Design Labs |
II |
| OrBec (oral beclomethasone dipropionate) |
Corticosteroid |
DOR BioPharma Inc. |
III |
| Thymoglobulin |
Anti-thymocyte globulin |
Genzyme |
II |
|
For more information contact us at clinicaltrials@cancerconsultants.com
 |
View Drugs in Pipeline By Disease |
 |
|
|
|
 |
|
 |
|
|